You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
SBC: CELDARA MEDICAL, LLC Topic: NIAIDPROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Automating Assessment of Contextualization of Care During the Clinical Encounter
SBC: Institute for Practice and Provider Performance Improvement, Inc. Topic: 600Background: Large scale studies have demonstrated that when patients struggle with life challenges that complicate their care (e.g., a lack of social support, competing responsibilities, or financial hardships), health care providers can improve health care outcomes and lower costs if they attempt to identify these “contextual factors” and address them in their care plan – a process termed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
PARCA (a digital tool) to improve Justice and Health
SBC: Q2I, LLC Topic: NIDAPROJECT SUMMARY/ABSTRACT Nearly 4.4 million individuals are on community supervision in the United States, with the majority (about 80%) being supervised under probation.1 Justice involved persons (JIPs) have a 474% increased lifetime experience with heroin, a 303% increased use of OxyContin in the last 12 months, and a 256% increased use in pain medication in the last 12 months, compared to the g ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis
SBC: GLYCOPATH INC Topic: 400Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Motion-Resistant Background Subtraction Angiography with Deep Learning:Real-Time, Edge Hardware Implementation and Product Development
SBC: CLEARVOYA LLC Topic: NHLBICatheter Digital Subtraction Angiography (DSA) is an imaging technique that was developed in the 1980s to allow physicians to visualize blood vessels. Today, this technology is utilized for minimally-invasive interventions that treat numerous devastating pathologies, including stroke and myocardial infarction, diseases that disproportionally impact underserved minority patient populations.Catheter ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
SBC: AcePre, LLC Topic: NIAAAProject Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide
SBC: OUI THERAPEUTICS INC Topic: 104ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development
SBC: FIBROTHERAPEUTICS INC Topic: NHLBIAbstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
SBC: Covira Surgical Topic: NIAIDSUMMARY Covira Surgical, Inc. is developing CS-0003, a first-in-class, orally administered non-antibiotic therapy for preventing infections in patients undergoing gastrointestinal (GI) surgeries. Despite improved surgical procedures, broad use of antibiotics, mandated asepsis measures, and enhanced recovery programs, post-surgical infections remain a clear and present danger to patients. Surgical ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
SBC: FibroBiologics, LLC Topic: NHLBIIdiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health